APOE and Alzheimer disease: Bapinezumab, a N-terminus (Aβ1–5)-directed antibody able to bind fibrillar, oligomeric, and monomeric forms of the peptide, was the first to be tested in a phase III development program consisting of four randomised, double-blind, placebo-controlled, phase III trials conducted in parallel on mild to moderate AD patients with (carriers) or without (non-carriers) the APOE ε4 genotype (Table 1).